Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

Roger A Barker; Mart Saarma; Clive N Svendsen; Catherine Morgan; Alan Whone; Massimo S Fiandaca; Matthias Luz; Krystof S Bankiewicz; Brian Fiske; Lyndsey Isaacs; Arthur Roach; Thomas Phipps; Jeffrey H Kordower; Emma L Lane; Henri J Huttunen; Aideen Sullivan; Gerard O'Keeffe; Valeria Yartseva; Howard Federoff

doi:10.1177/1877718X241301041

Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

Roger A Barker^*, Mart Saarma, Clive N Svendsen, Catherine Morgan, Alan Whone, Massimo S Fiandaca, Matthias Luz, Krystof S Bankiewicz, Brian Fiske, Lyndsey Isaacs, Arthur Roach, Thomas Phipps, Jeffrey H Kordower, Emma L Lane, Henri J Huttunen, Aideen Sullivan, Gerard O'Keeffe, Valeria Yartseva, Howard Federoff

^*Corresponding author for this work

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

7 Citations (Scopus)

Abstract

In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019. 1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial. 2 We then concluded with our recommendations on how GF studies in PD should develop going forward.

Original language	English
Pages (from-to)	1659-1676
Number of pages	18
Journal	Journal of Parkinson's Disease
Volume	14
Issue number	8
DOIs	https://doi.org/10.1177/1877718X241301041
Publication status	Published - 1 Nov 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Keywords

Parkinson Disease/drug therapy
Humans
Nerve Growth Factors/therapeutic use

Access to Document

10.1177/1877718X241301041Licence: CC BY-NC

Handle.net

Persistent link

Cite this

Barker, R. A., Saarma, M., Svendsen, C. N., Morgan, C., Whone, A., Fiandaca, M. S., Luz, M., Bankiewicz, K. S., Fiske, B., Isaacs, L., Roach, A., Phipps, T., Kordower, J. H., Lane, E. L., Huttunen, H. J., Sullivan, A., O'Keeffe, G., Yartseva, V., & Federoff, H. (2024). Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop. Journal of Parkinson's Disease, 14(8), 1659-1676. https://doi.org/10.1177/1877718X241301041

@article{1e1babf05f134b34862f49e4fdfa43d7,

title = "Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop",

abstract = "In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019. 1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial. 2 We then concluded with our recommendations on how GF studies in PD should develop going forward. ",

keywords = "Parkinson Disease/drug therapy, Humans, Nerve Growth Factors/therapeutic use",

author = "Barker, \{Roger A\} and Mart Saarma and Svendsen, \{Clive N\} and Catherine Morgan and Alan Whone and Fiandaca, \{Massimo S\} and Matthias Luz and Bankiewicz, \{Krystof S\} and Brian Fiske and Lyndsey Isaacs and Arthur Roach and Thomas Phipps and Kordower, \{Jeffrey H\} and Lane, \{Emma L\} and Huttunen, \{Henri J\} and Aideen Sullivan and Gerard O'Keeffe and Valeria Yartseva and Howard Federoff",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = nov,

day = "1",

doi = "10.1177/1877718X241301041",

language = "English",

volume = "14",

pages = "1659--1676",

journal = "Journal of Parkinson's Disease",

issn = "1877-7171",

publisher = "SAGE Publications Ltd",

number = "8",

}

Barker, RA, Saarma, M, Svendsen, CN, Morgan, C , Whone, A, Fiandaca, MS, Luz, M, Bankiewicz, KS, Fiske, B, Isaacs, L, Roach, A, Phipps, T, Kordower, JH, Lane, EL, Huttunen, HJ, Sullivan, A, O'Keeffe, G, Yartseva, V & Federoff, H 2024, 'Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop', Journal of Parkinson's Disease, vol. 14, no. 8, pp. 1659-1676. https://doi.org/10.1177/1877718X241301041

TY - JOUR

T1 - Neurotrophic factors for Parkinson's disease

T2 - Current status, progress, and remaining questions. Conclusions from a 2023 workshop

AU - Barker, Roger A

AU - Saarma, Mart

AU - Svendsen, Clive N

AU - Morgan, Catherine

AU - Whone, Alan

AU - Fiandaca, Massimo S

AU - Luz, Matthias

AU - Bankiewicz, Krystof S

AU - Fiske, Brian

AU - Isaacs, Lyndsey

AU - Roach, Arthur

AU - Phipps, Thomas

AU - Kordower, Jeffrey H

AU - Lane, Emma L

AU - Huttunen, Henri J

AU - Sullivan, Aideen

AU - O'Keeffe, Gerard

AU - Yartseva, Valeria

AU - Federoff, Howard

PY - 2024/11/1

Y1 - 2024/11/1

N2 - In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019. 1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial. 2 We then concluded with our recommendations on how GF studies in PD should develop going forward.

AB - In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019. 1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial. 2 We then concluded with our recommendations on how GF studies in PD should develop going forward.

KW - Parkinson Disease/drug therapy

KW - Humans

KW - Nerve Growth Factors/therapeutic use

U2 - 10.1177/1877718X241301041

DO - 10.1177/1877718X241301041

M3 - Review article (Academic Journal)

C2 - 39957193

SN - 1877-7171

VL - 14

SP - 1659

EP - 1676

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 8

ER -

Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Fingerprint

Cite this